- Home
- RGLS vs FGB Comparison
RGLS vs FGB Comparison
Compare RGLS & FGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- FGB
- Stock Information
- Founded
- RGLS 2007
- FGB 2007
- Country
- RGLS United States
- FGB United States
- Employees
- RGLS N/A
- FGB N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- FGB Finance/Investors Services
- Sector
- RGLS Health Care
- FGB Finance
- Exchange
- RGLS Nasdaq
- FGB Nasdaq
- Market Cap
- RGLS 74.0M
- FGB 65.1M
- IPO Year
- RGLS 2012
- FGB N/A
- Fundamental
- Price
- RGLS $1.31
- FGB $4.61
- Analyst Decision
- RGLS Strong Buy
- FGB
- Analyst Count
- RGLS 6
- FGB 0
- Target Price
- RGLS $10.33
- FGB N/A
- AVG Volume (30 Days)
- RGLS 820.1K
- FGB 53.0K
- Earning Date
- RGLS 03-20-2025
- FGB 01-01-0001
- Dividend Yield
- RGLS N/A
- FGB 8.92%
- EPS Growth
- RGLS N/A
- FGB N/A
- EPS
- RGLS N/A
- FGB N/A
- Revenue
- RGLS N/A
- FGB N/A
- Revenue This Year
- RGLS N/A
- FGB N/A
- Revenue Next Year
- RGLS N/A
- FGB N/A
- P/E Ratio
- RGLS N/A
- FGB N/A
- Revenue Growth
- RGLS N/A
- FGB N/A
- 52 Week Low
- RGLS $0.83
- FGB $2.85
- 52 Week High
- RGLS $3.79
- FGB $3.74
- Technical
- Relative Strength Index (RSI)
- RGLS 53.78
- FGB 67.16
- Support Level
- RGLS $1.22
- FGB $4.45
- Resistance Level
- RGLS $1.60
- FGB $4.55
- Average True Range (ATR)
- RGLS 0.13
- FGB 0.07
- MACD
- RGLS 0.03
- FGB 0.01
- Stochastic Oscillator
- RGLS 50.85
- FGB 87.64
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.